GeneDx Holdings (WGS) Stock Forecast: StockMap's 2-Week Call
WGS stock forecast: StockMap's model makes no two-week call on GeneDx Holdings after the Nov 19 close: its evidence is split, 8 reasons for and 7 against. Right in 3 of 4 two-week windows on WGS since Aug 26; by chance, a call on the same dates was right 71% of the time.
GeneDx Holdings last closed at $49.24, -5.23% on the session.
Against the IVW growth benchmark the position is -2.90% over the forecast window.
GeneDx Holdings' market cap is $1.48B as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -8 (too close to call).
Where WGS sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 8 bullish and 7 bearish.
Agreement across those insights is 47%.
19 daily calls for WGS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks GeneDx Holdings in the 20th percentile on return on equity, where 100 is best.
GeneDx Holdings is classified under Health Care / Health Care Providers & Services.
StockMap tracks GeneDx Holdings as the 48th largest of the 87 companies it covers in the Health Care Providers & Services industry, part of the Health Care sector.
Across that group the current two-week reads are 52 Neutral, 18 Moderate Underperform, 12 Moderate Outperform and 5 Strong Underperform.
On that composite GeneDx Holdings ranks 54th of 87 in the group, against a group median of -0.06.